Sonja Loges
Prof. Dr. med. Dr. rer. nat.
Sonja Loges
  • Medical Specialist in Internal Medicine and Hematology and Oncology
  • Working area 1
German (Mother tongue)

Areas of expertise


  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005
  • 2004
  • 2003
  • 2002

Sexual dimorphism in solid and hematological malignancies
Ben-Batalla I, Vargas-Delgado M, Meier L, Loges S
SEMIN IMMUNOPATHOL. 2019;41(2):251-263.

Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
Janning M, Kobus F, Babayan A, Wikman H, Velthaus J, Bergmann S, Schatz S, Falk M, Berger L, Böttcher L, Päsler S, Gorges T, O'Flaherty L, Hille C, Joosse S, Simon R, Tiemann M, Bokemeyer C, Reck M, Riethdorf S, Pantel K, Loges S
CANCERS. 2019;11(6):.

Personalisierte Krebstherapie 2018-Fiktion oder Wirklichkeit?
Loges S, Bokemeyer C
InFo Onkologie. 2019;21 (S1):3-5.

High Aldehyde Dehydrogenase Levels Are Detectable in the Serum of Patients with Lung Cancer and May Be Exploited as Screening Biomarkers
Rossi A, Voigtländer M, Klose H, Schlüter H, Schön G, Loges S, Paolini M, Bokemeyer C, Reck M, Tarro G, Binder M
Journal of oncology. 2019;2019:8970645.

EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients
Scharpenseel H, Hanssen A, Loges S, Mohme M, Bernreuther C, Peine S, Lamszus K, Goy Y, Petersen C, Westphal M, Glatzel M, Riethdorf S, Pantel K, Wikman H
SCI REP-UK. 2019;9(1):7406.

Aufbau von Strukturen zur Patientenversorgung
Velthaus J, Bokemeyer C, Loges S
InFo Onkologie. 2019;21(2):10-18.

Blockade of myeloid-derived suppressor cell expansion with all-trans retinoic acid increases the efficacy of anti-angiogenic therapy
Bauer R, Udonta F, Wroblewski M, Ben-Batalla I, Santos I, Taverna F, Kuhlencord M, Gensch V, Päsler S, Vinckier S, Brandner J, Pantel K, Bokemeyer C, Vogl T, Roth J, Carmeliet P, Loges S
CANCER RES. 2018;78(12):3220-3232.

Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib
Berger L, Janning M, Velthaus J, Ben-Batalla I, Schatz S, Falk M, Iglauer P, Simon R, Cao R, Forcato C, Manaresi N, Bramlett K, Buson G, Hanssen A, Tiemann M, Sauter G, Bokemeyer C, Riethdorf S, Reck M, Pantel K, Wikman H, Loges S
J THORAC ONCOL. 2018;13(12):e243-e246.

RAISEing VEGF-D's importance as predictive biomarker for ramucirumab in metastatic colorectal cancer patients
Carmeliet P, Li X, Treps L, Conradi L, Loges S
ANN ONCOL. 2018;29(3):527-529.

Frequency of Circulating Tumor Cells (CTC) in Patients with Brain Metastases: Implications as a Risk Assessment Marker in Oligo-Metastatic Disease
Hanssen A, Riebensahm C, Mohme M, Joosse S, Velthaus J, Berger L, Bernreuther C, Glatzel M, Loges S, Lamszus K, Westphal M, Riethdorf S, Pantel K, Wikman H
CANCERS. 2018;10(12):E527.

Anti-Angiogenics: Their Value in Lung Cancer Therapy
Janning M, Loges S
ONCOL RES TREAT. 2018;41(4):172-180.

Management immunvermittelter Nebenwirkungen - CME Fortbildung
Janning M, Loges S
hautnah Dermatologie. 2018;34(1):38-46.

BET-inhibition by JQ1 promotes proliferation and self-renewal capacity of hematopoietic stem cells
Wroblewski M, Scheller-Wendorff M, Udonta F, Bauer R, Schlichting J, Zhao L, Ben Batalla I, Gensch V, Päsler S, Wu L, Wanior M, Taipaleenmäki H, Bolamperti S, Najafova Z, Pantel K, Bokemeyer C, Qi J, Hesse E, Knapp S, Johnsen S, Loges S
HAEMATOLOGICA. 2018;103(6):939-948.

T-cell diversification reflects antigen selection in the blood of patients on immune checkpoint inhibition and may be exploited as liquid biopsy biomarker
Akyüz N, Brandt A, Stein A, Schliffke S, Mährle T, Quidde J, Goekkurt E, Loges S, Haalck T, Ford C, Asemissen A, Thiele B, Radloff J, Thenhausen T, Krohn-Grimberghe A, Bokemeyer C, Binder M
INT J CANCER. 2017;140(11):2535-2544.

Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia
Ben Batalla I, Erdmann R, Jørgensen H, Mitchell R, Ernst T, von Amsberg G, Schafhausen P, Velthaus J, Rankin S, Clark R, Koschmieder S, Schultze A, Mitra S, Vandenberghe P, Brümmendorf T, Carmeliet P, Hochhaus A, Pantel K, Bokemeyer C, Helgason G, Holyoake T, Loges S
CLIN CANCER RES. 2017;23(9):2289-2300.

Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-KPolymorphism
Braig F, Kriegs M, Voigtlaender M, Habel B, Grob T, Biskup K, Blanchard V, Sack M, Thalhammer A, Ben Batalla I, Braren I, Laban S, Danielczyk A, Goletz S, Jakubowicz E, Märkl B, Trepel M, Knecht R, Riecken K, Fehse B, Loges S, Bokemeyer C, Binder M
CANCER RES. 2017;77(5):1188-1199.

Management immunvermittelter Nebenwirkungen - CME Fortbildung
Janning M, Loges S
InFo Onkologie. 2017;20(S1):54-64.

A combination of low-dose bevacizumab and imatinib enhances vascular normalisation without inducing extracellular matrix deposition
Schiffmann L, Brunold M, Liwschitz M, Goede V, Loges S, Wroblewski M, Quaas A, Alakus H, Stippel D, Bruns C, Hallek M, Kashkar H, Hacker U, Coutelle O
BRIT J CANCER. 2017;116(5):600-608.

Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme B
Wroblewski M, Bauer R, Cubas Córdova M, Udonta F, Ben-Batalla I, Legler K, Hauser C, Egberts J, Janning M, Velthaus J, Schulze C, Pantel K, Bokemeyer C, Loges S
NAT COMMUN. 2017;8(1):269.

Characterization of different CTC subpopulations in non-small cell lung cancer
Hanssen A, Wagner J, Gorges T, Tänzer A, Uzunoglu F, Driemel C, Stoecklein N, Knoefel W, Angenendt S, Hauch S, Atanackovic D, Loges S, Riethdorf S, Pantel K, Wikman H
SCI REP-UK. 2016;6:28010.

A novel microfluidic platform for size and deformability based separation and the subsequent molecular characterization of viable circulating tumor cells
Hvichia G, Parveen Z, Wagner C, Janning M, Quidde J, Stein A, Müller V, Loges S, Neves R, Stoecklein N, Wikman H, Riethdorf S, Pantel K, Gorges T
INT J CANCER. 2016;138(12):2894-904.

TAM receptors Tyro3 and Mer as novel targets in colorectal cancer
Schmitz R, Valls A, Yerbes R, von Richter S, Kahlert C, Loges S, Weitz J, Schneider M, Ruiz de Almodovar C, Ulrich A, Schmidt T
ONCOTARGET. 2016;7(35):56355-56370.

Effects of p38α/β inhibition on acute lymphoblastic leukemia proliferation and survival in vivo
Alsadeq A, Strube S, Krause S, Carlet M, Jeremias I, Vokuhl C, Loges S, Aguirre-Ghiso J, Trauzold A, Cario G, Stanulla M, Schrappe M, Schewe D
LEUKEMIA. 2015;29(12):2307-16.

Cyclooxygenase-2 blockade can improve efficacy of VEGF-targeting drugs
Ben-Batalla I, Cubas-Cordova M, Udonta F, Wroblewski M, Waizenegger J, Janning M, Sawall S, Gensch V, Zhao L, Martinez-Zubiaurre I, Riecken K, Fehse B, Pantel K, Bokemeyer C, Loges S
ONCOTARGET. 2015;6(8):6341-58.

Epidermal growth factor receptor mutation mediates cross-resistance to panitumumab and cetuximab in gastrointestinal cancer
Braig F, März M, Schieferdecker A, Schulte A, Voigt M, Stein A, Grob T, Alawi M, Indenbirken D, Kriegs M, Engel E, Vanhoefer U, Grundhoff A, Loges S, Riecken K, Fehse B, Bokemeyer C, Binder M
ONCOTARGET. 2015;6(14):12035-47.

Acute Myelogenous Leukemia and its Microenvironment: A Molecular Conversation
Ghiaur G, Wroblewski M, Loges S
SEMIN HEMATOL. 2015;52(3):200-6.

Detection of Circulating Tumor Cells in Non-Small Cell Lung Cancer
Hanssen A, Loges S, Pantel K, Wikman-Kocher H
Front Oncol. 2015;5:Art. 207.

Axl inhibition: a potential road to a novel acute myeloid leukemia therapy?
Janning M, Ben-Batalla I, Loges S
Expert Rev Hematol. 2015;8(2):135-8.

Kommentar zu: Neue Hoffnung beim fortgeschrittenen Plattenepithelkarzinom der Lunge
Klein F, Loges S
Im Focus Onkologie. 2015;(10):30-31.

Mer tyrosine kinase promotes the survival of t(1;19)-positive acute lymphoblastic leukemia (ALL) in the central nervous system (CNS)
Krause S, Pfeiffer C, Strube S, Alsadeq A, Fedders H, Vokuhl C, Loges S, Waizenegger J, Ben-Batalla I, Cario G, Möricke A, Stanulla M, Schrappe M, Schewe D
BLOOD. 2015;125(5):820-30.

Role of Growth arrest-specific gene 6-Mer axis in multiple myeloma
Waizenegger J, Ben-Batalla I, Weinhold N, Meissner T, Wroblewski M, Janning M, Riecken K, Binder M, Atanackovic D, Taipaleenmaeki H, Schewe D, Sawall S, Gensch V, Cubas-Cordova M, Seckinger A, Fiedler W, Hesse E, Kröger N, Fehse B, Hose D, Klein B, Raab M, Pantel K, Bokemeyer C, Loges S
LEUKEMIA. 2015;29(3):696-704.

Expression of Hedgehog Pathway Mediator GLI Represents a Negative Prognostic Marker in Human Acute Myeloid Leukemia and Its Inhibition Exerts Antileukemic Effects
Wellbrock J, Latuske E, Köhler J, Wagner K, Stamm H, Vettorazzi E, Vohwinkel G, Klokow M, Uibeleisen R, Ehm P, Riecken K, Loges S, Thol F, Schubert C, Amling M, Jücker M, Bokemeyer C, Heuser M, Krauter J, Fiedler W

Bromodomain protein BRD4 is required for estrogen receptor-dependent enhancer activation and gene transcription
Nagarajan S, Hossan T, Alawi M, Najafova Z, Indenbirken D, Bedi U, Taipaleenmäki H, Ben-Batalla I, Scheller M, Loges S, Knapp S, Hesse E, Chiang C, Grundhoff A, Johnsen S
CELL REP. 2014;8(2):459-468.

Denosumab mimics the natural decoy receptor osteoprotegerin by interacting with its major binding site on RANKL
Schieferdecker A, Voigt M, Riecken K, Braig F, Schinke T, Loges S, Bokemeyer C, Fehse B, Binder M
ONCOTARGET. 2014;5(16):6647-53.

Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma
Ben Batalla I, Schultze A, Wroblewski M, Erdmann R, Heuser M, Waizenegger J, Riecken K, Binder M, Schewe D, Sawall S, Witzke V, Cubas Cordova M, Janning M, Wellbrock J, Fehse B, Hagel C, Krauter J, Ganser A, Lorens J, Fiedler W, Carmeliet P, Pantel K, Bokemeyer C, Loges S
BLOOD. 2013;122(14):2443-52.

Safe TNF-based antitumor therapy following p55TNFR reduction in intestinal epithelium
Van Hauwermeiren F, Armaka M, Karagianni N, Kranidioti K, Vandenbroucke R, Loges S, Van Roy M, Staelens J, Puimège L, Palagani A, Berghe W, Victoratos P, Carmeliet P, Libert C, Kollias G
J CLIN INVEST. 2013;123(6):2590-603.

Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer
Welti J, Loges S, Dimmeler S, Carmeliet P
J CLIN INVEST. 2013;123(8):3190-200.

Macrophage-tumor crosstalk: role of TAMR tyrosine kinase receptors and of their ligands.
Schmidt T, Ben-Batalla I, Schultze A, Loges S
CELL MOL LIFE SCI. 2012;69(9):1391-1414.

VEGFR-1 expression levels predict occurrence of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma
Schultze A, Ben Batalla I, Riethdorf S, Bubenheim M, Yekebas E, Erbersdobler A, Reichelt U, Effenberger K, Schmidt T, Izbicki J, Bokemeyer C, Pantel K, Fiedler W, Loges S
CLIN EXP METASTAS. 2012;29(8):879-87.

VEGFR-1 expression levels predict occurrence of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma.
Schultze A, Ben-Batalla I, Riethdorf S, Bubenheim M, Yekebas E, Erbersdobler A, Reichelt U, Harms-Effenberger K, Schmidt T, Izbicki J, Bokemeyer C, Pantel K, Fiedler W, Loges S
CLIN EXP METASTAS. 2012;29(8):879-887.

Phenotypic detection of clonotypic B cells in multiple myeloma by specific immunoglobulin ligands reveals their rarity in multiple myeloma.
Trepel M, Martens V, Doll C, Rahlff J, Gösch B, Loges S, Binder M
PLOS ONE. 2012;7(2):31998.

A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours.
Beck B, Driessens G, Goossens S, Youssef K, Kuchnio A, Caauwe A, Sotiropoulou P, Loges S, Lapouge G, Candi A, Mascre G, Drogat B, Dekoninck S, Haigh J, Carmeliet P, Blanpain C
NATURE. 2011;478(7369):399-403.

Expression of TGF-β receptor ALK-5 has a negative impact on outcome of patients with acute myeloid leukemia
Otten J, Schmitz L, Vettorazzi E, Schultze A, Marx A, Simon R, Krauter J, Loges S, Sauter G, Bokemeyer C, Fiedler W
LEUKEMIA. 2011;25(2):375-9.

Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia.
Schmidt T, Behzad K, Loges S, Cauwenberghs S, Fraisl P, Maes C, Jonckx B, Kim D, Kleppe M, Tjwa M, Schenk T, Vinckier S, Fragoso R, Maria D, Beel K, Dias S, Verfaillie C, Clark R, Brümmendorf T, Vandenberghe P, Rafii S, Holyoake T, Hochhaus A, Cools J, Karin M, Carmeliet G, Dewerchin M, Carmeliet P
CANCER CELL. 2011;19(6):740-753.

Role of delta-like-4/Notch in the formation and wiring of the lymphatic network in zebrafish
Geudens I, Herpers R, Hermans K, Segura I, Ruiz de Almodovar C, Bussmann J, De Smet F, Vandevelde W, Hogan B, Siekmann A, Claes F, Moore J, Pistocchi A, Loges S, Mazzone M, Mariggi G, Bruyère F, Cotelli F, Kerjaschki D, Noël A, Foidart J, Gerhardt H, Ny A, Langenberg T, Lawson N, Duckers H, Schulte-Merker S, Carmeliet P, Dewerchin M
ARTERIOSCL THROM VAS. 2010;30(9):1695-702.

Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates
Loges S, Schmidt T, Carmeliet P
Genes Cancer. 2010;1(1):12-25.

Malignant cells fuel tumor growth by educating infiltrating leukocytes to produce the mitogen Gas6
Loges S, Schmidt T, Tjwa M, van Geyte K, Lievens D, Lutgens E, Vanhoutte D, Borgel D, Plaisance S, Hoylaerts M, Luttun A, Dewerchin M, Jonckx B, Carmeliet P
BLOOD. 2010;115(11):2264-73.

Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease
Van de Veire S, Stalmans I, Heindryckx F, Oura H, Tijeras-Raballand A, Schmidt T, Loges S, Albrecht I, Jonckx B, Vinckier S, Van Steenkiste C, Tugues S, Rolny C, De Mol M, Dettori D, Hainaud P, Coenegrachts L, Contreres J, Van Bergen T, Cuervo H, Xiao W, Le Henaff C, Buysschaert I, Kharabi Masouleh B, Geerts A, Schomber T, Bonnin P, Lambert V, Haustraete J, Zacchigna S, Rakic J, Jiménez W, Noël A, Giacca M, Colle I, Foidart J, Tobelem G, Morales-Ruiz M, Vilar J, Maxwell P, Vinores S, Carmeliet G, Dewerchin M, Claesson-Welsh L, Dupuy E, Van Vlierberghe H, Christofori G, Mazzone M, Detmar M, Collen D, Carmeliet P
CELL. 2010;141(1):178-90.

Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way.
Carmeliet P, Frederik D, Loges S, Mazzone M
NAT REV CLIN ONCOL. 2009;6(6):315-326.

Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited.
Loges S, Mazzone M, Hohensinner P, Carmeliet P
CANCER CELL. 2009;15(3):167-170.

Development of targeted angiogenic medicine.
Loges S, Roncal C, Carmeliet P
J THROMB HAEMOST. 2009;7(1):21-33.

Antimyeloangiogenic therapy for cancer by inhibiting PlGF.
Loges S, Schmidt T, Carmeliet P
CLIN CANCER RES. 2009;15(11):3648-3653.

Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization.
Mazzone M, Dettori D, Rodrigo L, Loges S, Schmidt T, Jonckx B, Tian Y, Lanahan A, Pollard P, Carmen R, Frederik D, Vinckier S, Aragonés J, Debackere K, Luttun A, Wyns S, Jordan B, Pisacane A, Gallez B, Lampugnani M, Dejana E, Simons M, Ratcliffe P, Maxwell P, Carmeliet P
CELL. 2009;136(5):839-851.

Prognostic implication of expression of Angiopoietin-2 in acute myeloid leukemia.
Fiedler W, Schuch G, Loges S
LEUKEMIA RES. 2008;32(6):843-844.

Blood outgrowth endothelial cells from chronic myeloid leukaemia patients are BCR/ABL1 negative.
Wellbrock J, Schultze A, Schafhausen P, Otterstetter S, Dierlamm J, Bokemeyer C, Brümmendorf T, Fiedler W, Loges S
BRIT J HAEMATOL. 2008;142(1):115-118.

Hypoxia can induce c-Met expression in glioma cells and enhance SF/HGF-induced cell migration.
Eckerich C, Zapf S, Fillbrandt R, Loges S, Westphal M, Lamszus K
INT J CANCER. 2007;121(2):276-283.

Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels.
Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, Chorianopoulos E, Liesenborghs L, Koch M, Maria D, Autiero M, Wyns S, Plaisance S, Moons L, van Rooijen N, Giacca M, Stassen J, Dewerchin M, Collen D, Carmeliet P
CELL. 2007;131(3):463-475.

Lymphatic reprogramming of microvascular endothelial cells by CEA-related cell adhesion molecule-1 via interaction with VEGFR-3 and Prox1.
Kilic N, Oliveira-Ferrer L, Neshat-Vahid S, Irmak S, Obst-Pernberg K, Wurmbach J, Loges S, Kilic E, Weil J, Lauke-Wettwer H, Tilki D, Singer B, Ergün S
BLOOD. 2007;110(13):4223-4233.

Cilengitide inhibits proliferation and differentiation of human endothelial progenitor cells in vitro.
Loges S, Butzal M, Wellbrock J, Schweizer M, Fischer U, Bokemeyer C, Hossfeld D, Schuch G, Fiedler W
BIOCHEM BIOPH RES CO. 2007;357(4):1016-1020.

Determination of microvessel density by quantitative real-time PCR in esophageal cancer: correlation with histologic methods, angiogenic growth factor expression, and lymph node metastasis.
Loges S, Clausen H, Reichelt U, Bubenheim M, Erbersdobler A, Schurr P, Yekebas E, Schuch G, Izbicki J, Pantel K, Bokemeyer C, Fiedler W
CLIN CANCER RES. 2007;13(1):76-80.

Downregulation of VEGF-A, STAT5 and AKT in acute myeloid leukemia blasts of patients treated with SU5416.
Loges S, Tinnefeld H, Metzner A, Jücker M, Butzal M, Bruweleit M, Fischer U, Draab E, Schuch G, O'-Farrel A, Hossfeld D, Bokemeyer C, Fiedler W
LEUKEMIA LYMPHOMA. 2006;47(12):2601-2609.

Pro-angiogenic signaling by the endothelial presence of CEACAM1.
Kilic N, Oliveira-Ferrer L, Wurmbach J, Loges S, Chalajour F, Neshat-Vahid S, Vahid S, Weil J, Fernando M, Ergun S
J BIOL CHEM. 2005;280(3):2361-2369.

Analysis of concerted expression of angiogenic growth factors in acute myeloid leukemia: expression of angiopoietin-2 represents an independent prognostic factor for overall survival.
Loges S, Heil G, Bruweleit M, Schoder V, Butzal M, Fischer U, Gehling U, Schuch G, Hossfeld D, Fiedler W
J CLIN ONCOL. 2005;23(6):1109-1117.

Antiangiogenic treatment with endostatin inhibits progression of AML in vivo.
Schuch G, Oliveira-Ferrer L, Loges S, Laack E, Bokemeyer C, Hossfeld D, Fiedler W, Ergun S
LEUKEMIA. 2005;19(8):1312-1317.

Rapamycin inhibits proliferation and differentiation of human endothelial progenitor cells in vitro.
Butzal M, Loges S, Schweizer M, Fischer U, Gehling U, Hossfeld D, Fiedler W
EXP CELL RES. 2004;300(1):65-71.

An in vitro study on the mechanisms of coagulation activation in acute myelogenous leukemia (AML): role of tissue factor regulation by cytotoxic drugs and GM-CSF.
Langer F, Amirkhosravi A, Loges S, Meyer T, Eifrig B, Hossfeld D, Fiedler W, Francis J
THROMB HAEMOSTASIS. 2004;92(5):1136-1146.

Identification of the adult human hemangioblast.
Loges S, Fehse B, Brockmann M, Lamszus K, Butzal M, Guckenbiehl M, Schuch G, Ergün S, Fischer U, Zander A, Hossfeld D, Fiedler W, Gehling U
STEM CELLS DEV. 2004;13(3):229-242.

Dual role of carcinoembryonic antigen-related cell adhesion molecule 1 in angiogenesis and invasion of human urinary bladder cancer.
Oliveira-Ferrer L, Tilki D, Ziegeler G, Hauschild J, Loges S, Irmak S, Kilic E, Huland H, Friedrich M, Ergün S
CANCER RES. 2004;64(24):8932-8938.

A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia.
Fiedler W, Mesters R, Tinnefeld H, Loges S, Staib P, Duhrsen U, Flasshove M, Ottmann O, Jung W, Cavalli F, Kuse R, Thomalla J, Serve H, O'Farrell A, Jacobs M, Brega N, Scigalla P, Hossfeld D, Berdel W
BLOOD. 2003;102(8):2763-2767.

Highly efficient retroviral gene transfer based on centrifugation-mediated vector preloading of tissue culture vessels.
Kühlcke K, Fehse B, Schilz A, Loges S, Lindemann C, Ayuketang Ayuk F, Lehmann F, Stute N, Fauser A, Zander A, Eckert H
MOL THER. 2002;5(4):473-478.

Letzte Aktualisierung aus dem FIS: 13.11.2019 - 06:17 Uhr